Anti-VIP Antibody, clone 2N7 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 18 amino acids from the Vasoactive intestinal peptide, C-terminal half of human VIP.

Quality Control Testing

Evaluated by Western Blotting in SH-SY5Y cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected VIP in SH-SY5Y cell lysate.

Tested Applications

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected VIP in SH-SY5Y cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected VIP in human pancreas tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound VIP peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Vasoactive intestinal peptide (UniProt: P01282; also known as Vasoactive intestinal polypeptide) is encoded by the VIP gene (Gene ID: 7432) in human. VIP gene is mapped to human chromosome 6q25.2. Vasoactive intestinal peptide is a neuropeptide involved in a diverse array of physiological processes. It is a 28-amino acid peptide expressed in gastrointestinal tissues and neural tissues. It is abundantly expressed throughout the CNS and peripheral nervous systems where they primarily exert neuroprotective and immune modulatory roles. It is involved in the VIP biosynthetic pathways and also acts as a neurotransmitter in neural tissues. It works in the relaxation of smooth muscle, stimulation of intestinal water and electrolyte secretion and release of insulin, glucagon and several anterior pituitary hormones. VIP participates in vasodilation and acts as a potent agonist of the calcitonin receptor CALCR, with similar efficacy as calcitonin. Studies have shown that VIP signaling is crucial for maintaining gut homeostasis and has implications in diseases such as inflammatory bowel disease (IBD). Recent research suggested that VIP also plays a key role in microbial-neuroimmune control of intestinal motility. Functional role of VIP in various pulmonary diseases has also been extensively studied and although, VIP is known to have a protective effect in pulmonary hypertension and asthma, it has been suggested to promote tumor growth in lung cancer. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Bai, X., et al. (2024). Cell Mol Gastroenterol Hepatol. 17(3); 383-398; Zhong, HL., et al. (2023). Life Sciences. 332; 122121).

Clone 2N7 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects VIP. It targets an epitope within 18 amino acids from the Vasoactive intestinal peptide.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.